Tags : Five Biosimilars

JAMP Signs an Agreement with Alvotech to Commercialize Five Biosimilars

Shots: JAMP to get exclusive commercialization right for Alvotech’s five biosimilar therapies, having the market value of ~2B annually in Canada The collaboration allows JAMP to expand its generic portfolio, expected to exceed 500 products by 2022 and now has six biosimilars in its pipeline leading to an improvement in patient access to the therapies […]Read More